IOF LogoIOF World Congress on Osteoporosis 2004, May 14-18, 2004, Rio de Janeiro, Brazil
IOF Website  |  IOF World Congress 2006
Your Account: Log in or Register
Congress Homepage
Scientific Committee
Scientific Program
Press releases
Exhibitors / Sponsors
Version Española
Versão Portuguêsa

The IOF World Congress on Osteoporosis website is supported by an unrestricted educational grant from Pfizer

Pfizer

Exhibitors

Logo Aventis

Booth: N° 1 (Area A )

Company Showcase

Aventis: Global Reach

Aventis has a commercial presence in approximately 85 countries and our products are available in more than 170. The top four markets are the United States, Germany, France and Japan. In 2003, Aventis generated 62.5% of our core business sales in these countries.

Accounting for over 40% of global prescription drug sales, the United States is the world's largest pharmaceutical market and our single largest national market. In 2003, we generated 38% of our core business sales in the U.S. In Europe, our leading markets are France, Germany, Italy, Spain and the United Kingdom. Japan, the world's second-largest national market, accounted for 5% of our core business sales in 2003.

Our Commercial Operations team is aiming to achieve higher product sales by pursuing more ambitious, locally driven global commercial strategies aimed at maximizing the potential of our global strategic brands.

In the U.S., our prescription drug business is conducted by Aventis Pharmaceuticals Inc., which is headquartered in Bridgewater, New Jersey. In 2003, U.S. sales (including human vaccines) amounted to EUR 6.4 billion, equivalent to 38% of our total core business sales. Our short-term goal is to increase the share of sales in the world's largest pharmaceutical market to more than 40%.

Aventis Pharma S.A. is the largest pharmaceutical company in France. In 2003, sales by Aventis in France totaled EUR 2.1 billion, making France the second-largest national market for Aventis.

In 2003, Aventis in Germany generated sales totaling EUR 1.1 billion. Germany is the company's third-largest market by sales and is also one of the three strategic locations for research and development as well as production and manufacturing. Aventis Pharma Deutschland is the leading pharmaceutical company in terms of R&D; investments in Germany.

In Japan, we achieved sales of EUR 847 million in 2003. 2003 saw the approval and launch of Lantus and Ketek , two of our core strategic brands. Aventis Pharma (Japan) Ltd. is one of the leading non-domestic pharmaceutical companies in Japan and ranks fourth in terms of country sales by Aventis.

In Latin America, we are one of the leading pharmaceutical companies in Mexico, Brazil and Argentina.

Strong sales force

Aventis has a global sales force of nearly 20 000. At the end of 2003, we had approximately 4 400 sales reps in the United States. Thanks to the strength and capabilities of our sales force, we have formed many partnerships to co-promote / co-market certain products in specific geographic areas. Major arrangements currently include an agreement with Procter & Gamble for the osteoporosis drug Actonel, with Teva Pharmaceuticals for the multiple sclerosis drug Copaxone, with Yakult for Campto, and with Daiichi for Tavanic.

 

Back to:

Company Profile
Floor plan
Exhibitors and Sponsors

Page Top

© 2004 International Osteoporosis Foundation Web design and programming by Zephir Software Design